Literature DB >> 34720150

Evaluation of Outcomes in Patients Receiving Amantadine to Improve Alertness After Traumatic Brain Injury.

Rim M Hadgu1,2, Amne Borghol1, Christopher Gillard1, Candice Wilson1, Suzan Elqess Mossa1, Megan McKay1, Charles Jastram3, Ifeanyi O Onor1.   

Abstract

Background: Amantadine has been used off-label to improve alertness after traumatic brain injury (TBI). The goal of this study is to assess the mean change at 72 hours and in course of therapy (COT) Glasgow Coma Scale (GCS) score after amantadine initiation and to correlate the change in GCS score with participation in physical therapy (PT) and occupational therapy (OT) among patients with TBI receiving amantadine during the first hospitalization.
Methods: This single-center, retrospective, cohort study included patients ≥18 years old hospitalized for a TBI from August 2012 to February 2018 and received ≥1 dose of amantadine to increase alertness. The primary endpoint is the mean change in 72-hour GCS score after amantadine initiation. The secondary endpoint is the mean change in COT GCS score after amantadine initiation and the correlation between the change in GCS score and percent PT and OT participation at 72 hours and during the COT.
Results: Seventy-nine patients were included. The mean age of patients was 41 years, and 79.8% of the patients were men. The mean change in 72-hour GCS score was +0.75 (95% confidence interval [CI] = 0.09-1.42, P = .027), and the mean change in COT GCS score was +2.29 (95% CI = 1.68-2.90, P < .001). There was no significant correlation between the increase in GCS score and percent PT/OT session participation at 72 hours and during the COT, r = -0.15 (P = .24) and r = -0.02 (P = .74), respectively. The percent PT/OT session participation at 72-hour post-amantadine initiation was 61.3% compared with 65.9% during the COT.
Conclusion: There were small but statistically significant increases in the mean change at 72 hours and in COT GCS score; however, they were not correlated with percent PT/OT participation. Other studies are needed to determine the appropriate time and GCS score to initiate amantadine along with the optimal dose in the inpatient setting.
© The Author(s) 2020.

Entities:  

Keywords:  alertness; amantadine; traumatic brain injury

Year:  2020        PMID: 34720150      PMCID: PMC8554610          DOI: 10.1177/0018578720920803

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  18 in total

1.  Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study.

Authors:  Mary A McMahon; Jilda N Vargus-Adams; Linda J Michaud; Judy Bean
Journal:  Am J Phys Med Rehabil       Date:  2009-07       Impact factor: 2.159

2.  Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans.

Authors:  J I Brown; A J Baker; S J Konasiewicz; R J Moulton
Journal:  J Neurotrauma       Date:  1998-04       Impact factor: 5.269

3.  Placebo-controlled trial of amantadine for severe traumatic brain injury.

Authors:  Joseph T Giacino; John Whyte; Emilia Bagiella; Kathleen Kalmar; Nancy Childs; Allen Khademi; Bernd Eifert; David Long; Douglas I Katz; Sooja Cho; Stuart A Yablon; Marianne Luther; Flora M Hammond; Annette Nordenbo; Paul Novak; Walt Mercer; Petra Maurer-Karattup; Mark Sherer
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Assessment of coma and impaired consciousness. A practical scale.

Authors:  G Teasdale; B Jennett
Journal:  Lancet       Date:  1974-07-13       Impact factor: 79.321

Review 5.  Glutamate and GABA imbalance following traumatic brain injury.

Authors:  Réjean M Guerriero; Christopher C Giza; Alexander Rotenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 6.  Therapeutic options to enhance coma arousal after traumatic brain injury: state of the art of current treatments to improve coma recovery.

Authors:  Giulia Cossu
Journal:  Br J Neurosurg       Date:  2013-10-03       Impact factor: 1.596

Review 7.  Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes.

Authors:  Brendan T Carroll; Harold W Goforth; Christopher Thomas; Niraj Ahuja; William W McDaniel; Marilyn F Kraus; David R Spiegel; Kathleen N Franco; Leopold Pozuelo; Camilo Muñoz
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

Review 8.  Novel approach to the role of NMDA receptors in traumatic brain injury.

Authors:  Esther Shohami; Anat Biegon
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

9.  Cognitive and Functional Outcomes following Inpatient Rehabilitation in Patients with Acquired Brain Injury: A Prospective Follow-up Study.

Authors:  Maitreyi Patil; Anupam Gupta; Meeka Khanna; Arun B Taly; Amit Soni; J Keshav Kumar; K Thennarasu
Journal:  J Neurosci Rural Pract       Date:  2017 Jul-Sep

Review 10.  The impact of extended bed rest on the musculoskeletal system in the critical care environment.

Authors:  Selina M Parry; Zudin A Puthucheary
Journal:  Extrem Physiol Med       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.